NCT03000218 is a Phase 1 clinical trial of Ursodeoxycholic acid in Overweight, sponsored by Seoul National University Hospital.

Who is sponsoring NCT03000218?

NCT03000218 is sponsored by Seoul National University Hospital.

What drugs are being tested in NCT03000218?

Interventions in NCT03000218: Ursodeoxycholic acid, Metformin, Placebo.

What condition does NCT03000218 study?

NCT03000218 studies Overweight, Abnormal Liver Function Tests.

Is NCT03000218 still recruiting?

NCT03000218 is currently status unknown. Last updated 22 December 2016.

Last reviewed 2016-12-22 · How we verify

NCT03000218

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study Evaluating Pharmacokinetics and Biomarkers After Ursodeoxycholic Acid (UDCA) Administration to Subjects Who Are Overweight and Have Liver Problems

Status unknown Phase 1 Last updated 22 December 2016

What this trial tests

Phase 1 trial testing Ursodeoxycholic acid in Overweight in 30 participants. Status unknown.

Timeline

1 August 2016

Primary endpoint
1 June 2017

Quick facts

Lead sponsor	Seoul National University Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 August 2016
Primary completion	1 June 2017
Sites	1 location across South Korea

Drugs / interventions tested

Ursodeoxycholic acid — full drug profile →
Metformin (metformin) — full drug profile →
Placebo

Conditions studied

Overweight — all drugs for Overweight →
Abnormal Liver Function Tests — all drugs for Abnormal Liver Function Tests →

Sponsor

Seoul National University Hospital

Who can join

Adults 18 to 50, any sex, with Overweight or Abnormal Liver Function Tests. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Area under the plasma concentration-time curve (AUC) of ursodeoxycholic acid
Time frame: Day 1, 15, 29, 57 predose (0h), Day 29 1, 2, 3, 4h
Change from Baseline Low-density lipoprotein cholesterol at 8 weeks
Time frame: Day 1, 29, 57, 71 predose (0h)

Sponsor's own description

A clinical study to evaluate pharmacokinetics, metabolomics and biomarker in subjects who are overweight and have liver problems after ursodeoxycholic acid multiple administration

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction.
Kim DJ, Yoon S, Ji SC, Yang J, et al · · 2018 · cited 57× · PMID 30089798 · DOI 10.1038/s41598-018-30349-1

Verify or expand the search:

Other trials of Ursodeoxycholic acid

Trials testing the same drug.

NCT06517862 — Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia · Phase 4 · recruiting
NCT06091787 — Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor Hepatectomy · NA · completed
NCT05902468 — Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus · Phase 2, PHASE3 · unknown
NCT05467553 — A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection · Phase 2 · unknown
NCT05690646 — Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery · Phase 4 · unknown

Other recruiting trials for Overweight

Currently open trials in the same condition.

NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
NCT07465965 — A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults · Phase 1 · recruiting
NCT07407348 — A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the · Phase 1 · recruiting
NCT07400653 — A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) · Phase 3 · recruiting

Other Seoul National University Hospital trials

Trials by the same sponsor.

NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03000218 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
Last refreshed: 22 December 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03000218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing